Smruthy Sivakumar, PhD, discusses results from a large-scale analysis of ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer. As genomic and precision medicine studies have historically underrepresented men of African ancestry, Sivakumar et al sought to shed light on disparities in this patient population.
The results were shared in as abstract as part of the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5003]). The study was conducted through a partnership between Foundation Medicine and the University of Miami Sylvester Comprehensive Cancer Center.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.